ACADIA Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACAD Nasdaq 2836 www.acadia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value? - Oct 5th, 2026 7:07 pm
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Sep 29th, 2026 7:06 am
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Sep 28th, 2026 2:05 pm
3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI - Sep 28th, 2026 9:30 am
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Sep 27th, 2026 1:09 am
ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets - Sep 25th, 2026 9:22 am
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - Sep 25th, 2026 9:02 am
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss - Sep 25th, 2026 9:01 am
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data - Sep 25th, 2026 7:21 am
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - Sep 24th, 2026 9:26 pm
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - Sep 24th, 2026 4:41 pm
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% - Sep 24th, 2026 3:51 pm
Bears Chase Down Acadia Pharma After Surprise Alzheimer's Setback - Sep 24th, 2026 2:13 pm
Sector Update: Healthcare Stocks Advance Late Afternoon - Sep 24th, 2026 2:01 pm
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data - Sep 24th, 2026 9:25 am
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial - Sep 24th, 2026 9:03 am
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - Sep 24th, 2026 7:56 am
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint - Sep 24th, 2026 5:47 am
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - Sep 24th, 2026 5:00 am
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report? - Sep 3rd, 2026 9:30 am